ACADIA PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (ACAD)

Historical Holders from Q1 2014 to Q1 2025

Symbol
ACAD on Nasdaq
CUSIP
004225108
Type / Class
Equity / Common Stock, par value $0.0001 per share
Shares outstanding
167M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
163M
Holdings value
$2.99B
% of all portfolios
0.005%
Grand Portfolio weight change
+0%
Number of holders
292
Number of buys
160
Number of sells
-100
Average Value change %
+0%
Average buys %
+0.002%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ACADIA PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (ACAD)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 11.9% $349M 19.9M BlackRock, Inc. Jan 31, 2025
RTW INVESTMENTS, LP 5.2% $153M 8.71M RTW Investments, LP Dec 31, 2024

Institutional Holders of ACADIA PHARMACEUTICALS INC - Common Stock, par value $0.0001 per share (ACAD)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 4.35M $72.3M +$24.6M $16.61 25
2024 Q4 163M $2.99B +$159M $18.35 292
2024 Q3 155M $2.38B -$124M $15.38 258
2024 Q2 161M $2.62B +$12.3M $16.25 265
2024 Q1 160M $2.95B -$59.9M $18.49 268
2023 Q4 159M $4.99B +$168M $31.31 271
2023 Q3 155M $3.23B -$78.8M $20.84 244
2023 Q2 157M $3.76B +$21.9M $23.95 229
2023 Q1 157M $2.96B +$53.6M $18.82 229
2022 Q4 156M $2.48B +$28.4M $15.92 219
2022 Q3 148M $2.42B +$23.5M $16.36 204
2022 Q2 150M $2.11B +$2.6M $14.09 224
2022 Q1 146M $3.55B -$24.6M $24.22 249
2021 Q4 148M $3.45B +$76.4M $23.34 234
2021 Q3 145M $2.4B -$86.1M $16.61 229
2021 Q2 148M $3.61B +$55.7M $24.39 235
2021 Q1 145M $3.73B -$222M $25.80 257
2020 Q4 147M $7.86B -$112M $53.46 296
2020 Q3 150M $6.18B -$101M $41.25 259
2020 Q2 153M $7.39B -$49.3M $48.47 291
2020 Q1 154M $6.49B +$187M $42.25 240
2019 Q4 149M $6.38B +$117M $42.78 268
2019 Q3 146M $5.26B +$305M $35.99 227
2019 Q2 138M $3.69B +$175M $26.73 193
2019 Q1 138M $3.7B -$504K $26.85 195
2018 Q4 139M $2.25B +$303M $16.17 173
2018 Q3 118M $2.45B +$122M $20.76 176
2018 Q2 117M $1.78B -$131M $15.27 178
2018 Q1 122M $2.74B +$37.7M $22.47 189
2017 Q4 120M $3.61B +$37.2M $30.11 204
2017 Q3 117M $4.4B -$40.7M $37.67 203
2017 Q2 118M $3.29B +$72.2M $27.89 195
2017 Q1 119M $4.11B +$169M $34.38 211
2016 Q4 120M $3.46B +$99.4M $28.84 214
2016 Q3 118M $3.75B +$217M $31.81 226
2016 Q2 110M $3.59B +$35.4M $32.46 222
2016 Q1 110M $3.07B +$338M $27.96 208
2015 Q4 97.4M $3.47B -$45.9M $35.65 207
2015 Q3 98.5M $3.26B +$12.9M $33.07 183
2015 Q2 97.4M $4.08B +$68M $41.88 186
2015 Q1 97.3M $3.17B +$38.3M $32.59 192
2014 Q4 96.2M $3.06B +$57.9M $31.75 180
2014 Q3 94.2M $2.33B -$12.9M $24.76 162
2014 Q2 95M $2.15B +$93.9M $22.59 158
2014 Q1 90.9M $2.21B +$190M $24.33 162